Bacteria Derived Small Molecules as Novel Antimicrobial Adjuvants for the Treatment of Nosocomial and Drug-Resistant Bacterial Infections
Technical Report,01 Jul 2016,30 Sep 2018
Research Institute of McGill University Health Centre Montreal Canada
Pagination or Media Count:
Pseudomonas aeruginosa PA and Staphylococcus aureus SA are among the ESKAPE organisms, and can cause severe and potentially fatal healthcare-acquired infections HAI such as pneumonia. The rise of these superbugs threatens our ability to treat severe HAI, and has awoken us to the urgent need for new antibacterial strategies. With the near absence of new classes of antibiotics, adjuvants that render bacteria more susceptible to existing antibiotics may broaden the spectrum of available drugs and overcome resistance. The purpose of our project is to explore the use of the bacteria-derived small molecules 4-hydroxyl-2-alkylquinolines HAQ as adjuvants to potentiate the activity of conventional bactericidal antibiotics. We hypothesize that HAQ potentiate the bactericidal activity of conventional antibiotics and can be used as adjuvants to treat infections recalcitrant to antibiotics. The objective of this proposal is to characterize the in vitro and in vivo adjuvant activity of HAQ used in combination with bactericidal antibiotics against major bacterial pathogens implicated in HAI.
- Medicine and Medical Research